Compare Raymond James Financial, Inc. (RJF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Raymond James Financial, Inc. trades at $158.66 (market cap $30.51B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Raymond James Financial, Inc. is far larger — about 14.3× Recursion Pharmaceuticals Inc's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 74 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RJF | RXRX | |
|---|---|---|
Market Cap | $30.51B | $2.14B |
Volume | 1,206,253 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $181.18 | $6.79 |
52-Week Low | $140.89 | $2.84 |
Typical Hold Time | 74 Days | 22 Days |
Enterprise Value | $24.37B | $1.66B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $157.29, down 1.4% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 forecast. Revenue growth is steady, reaching $13.84 billion in 2025, while profitability remains strong with a net income margin of 15.37%. Recent corporate news includes executive leadership appointments and a declared quarterly dividend of $0.54 per share.
The outlook is mixed, with a consensus analyst price target of $184.00 suggesting upside potential, but technical indicators signal near-term caution. Key risks include rising expenses and capital market volatility. The absence of sell ratings and solid institutional interest support a fundamentally sound investment case, though investors should weigh the bearish technical momentum against strong fundamentals.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
